Literature DB >> 20417026

Antiphospholipid syndrome and central nervous system.

Miroslav Mayer1, Mislav Cerovec, Marko Rados, Nada Cikes.   

Abstract

Classification criteria, etiology, pathogenesis, major central nervous system (CNS) manifestations of the antiphospholipid syndrome (APS), as well as diagnostic and therapeutic approach are discussed in the article, supported by several MRI findings to illustrate differential complexity of selected topics. Close interplay of inflammation, autoimmunity, coagulation cascade, vasculature bed, neuron physiology and demyelinization in APS is elaborated. Cerebrovascular disease, multiple sclerosis-like syndrome, seizures, cognitive disfunction, headache and migraine, chorea and catastrophic antiphospholipid syndrome (CAPS) are discussed as the most prominent CNS manifestations of the APS.

Entities:  

Mesh:

Year:  2010        PMID: 20417026     DOI: 10.1016/j.clineuro.2010.03.023

Source DB:  PubMed          Journal:  Clin Neurol Neurosurg        ISSN: 0303-8467            Impact factor:   1.876


  15 in total

Review 1.  Reversible cerebral vasoconstriction syndrome (RCVS) in antiphospholipid antibody syndrome (APLA): the role of centrally acting vasodilators. Case series and review of literature.

Authors:  Sarthak Gupta; Robert Zivadinov; Deepa Ramasamy; Julian L Ambrus
Journal:  Clin Rheumatol       Date:  2013-11-26       Impact factor: 2.980

2.  Basilar artery thrombosis in the setting of antiphospholipid syndrome.

Authors:  Amin F Saad; Larry T Nickell; R Evans Heithaus; Sadat A Shamim; Michael J Opatowsky; Kennith F Layton
Journal:  Proc (Bayl Univ Med Cent)       Date:  2014-07

Review 3.  Immunotherapies for Neurological Manifestations in the Context of Systemic Autoimmunity.

Authors:  Eleni I Kampylafka; Harry Alexopoulos; Marinos C Dalakas; Athanasios G Tzioufas
Journal:  Neurotherapeutics       Date:  2016-01       Impact factor: 7.620

4.  Diffusion tensor imaging in patients with obstetric antiphospholipid syndrome without neuropsychiatric symptoms.

Authors:  Fabricio R Pereira; Francesco Macri; Marcel P Jackowski; William J Kostis; Jean-Christophe Gris; Jean-Paul Beregi; Choukri Mekkaoui
Journal:  Eur Radiol       Date:  2015-07-23       Impact factor: 5.315

Review 5.  White matter lesions and vascular cognitive impairment: part 1: typical and unusual causes.

Authors:  M Nichtweiss; S Weidauer; N Treusch; E Hattingen
Journal:  Clin Neuroradiol       Date:  2012-02-11       Impact factor: 3.649

Review 6.  Neurologic Manifestations of Catastrophic Antiphospholipid Syndrome.

Authors:  Rafid Mustafa
Journal:  Curr Neurol Neurosci Rep       Date:  2022-08-30       Impact factor: 6.030

Review 7.  Antiphospholipid syndrome (APS) revisited: Would migraine headaches be included in future classification criteria?

Authors:  Mohammad Hassan A Noureldine; Ali A Haydar; Ahmad Berjawi; Rody Elnawar; Ahmad Sweid; Munther A Khamashta; Graham R V Hughes; Imad Uthman
Journal:  Immunol Res       Date:  2017-02       Impact factor: 2.829

Review 8.  Pathophysiology of the antiphospholipid antibody syndrome.

Authors:  Rohan Willis; Silvia S Pierangeli
Journal:  Auto Immun Highlights       Date:  2011-03-24

Review 9.  Aspirin and multiple sclerosis.

Authors:  Sheila Tsau; Mitchell R Emerson; Sharon G Lynch; Steven M LeVine
Journal:  BMC Med       Date:  2015-06-29       Impact factor: 8.775

10.  Is There an Increased Risk for Ischemic Stroke in Patients with Multiple Sclerosis, and If So, Should Preventive Treatment Be Considered?

Authors:  Steven M LeVine
Journal:  Front Neurol       Date:  2016-08-11       Impact factor: 4.003

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.